100 related articles for article (PubMed ID: 9223730)
21. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
[TBL] [Abstract][Full Text] [Related]
22. Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay.
Achkar JM; Wang XH; Nyambi P; Gorny MK; Zolla-Pazner S; Bandrés JC
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):203-10. PubMed ID: 10969343
[TBL] [Abstract][Full Text] [Related]
23. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
[TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
[TBL] [Abstract][Full Text] [Related]
25. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
26. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
Arendrup M; Nielsen C; Hansen JE; Pedersen C; Mathiesen L; Nielsen JO
J Acquir Immune Defic Syndr (1988); 1992; 5(3):303-7. PubMed ID: 1740756
[TBL] [Abstract][Full Text] [Related]
27. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
28. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
Burton DR; Pyati J; Koduri R; Sharp SJ; Thornton GB; Parren PW; Sawyer LS; Hendry RM; Dunlop N; Nara PL
Science; 1994 Nov; 266(5187):1024-7. PubMed ID: 7973652
[TBL] [Abstract][Full Text] [Related]
29. Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.
Vella C; Zheng NN; Easterbrook P; Daniels RS
AIDS Res Hum Retroviruses; 2002 Sep; 18(13):933-46. PubMed ID: 12230936
[TBL] [Abstract][Full Text] [Related]
30. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
31. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates.
Nichols CN; Bernal I; Prince AM; Andrus L
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):49-56. PubMed ID: 11804556
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
[TBL] [Abstract][Full Text] [Related]
34. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.
Lathey JL; Tsou J; Brinker K; Hsia K; Meyer WA; Spector SA
J Infect Dis; 1999 Aug; 180(2):344-50. PubMed ID: 10395848
[TBL] [Abstract][Full Text] [Related]
35. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1.
Scarlatti G; Leitner T; Hodara V; Halapi E; Rossi P; Albert J; Fenyö EM
AIDS; 1993 Nov; 7 Suppl 2():S45-8. PubMed ID: 8161445
[TBL] [Abstract][Full Text] [Related]
36. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
37. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
[TBL] [Abstract][Full Text] [Related]
38. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
39. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
